Alimta

...Market Strategies Announces 'HALO' Effect of ASCO 2005 Still Driving Oncologists' Prescribing Behavior for Genentech Yahoo!

My Yahoo!

Mail Welcome, Guest [Sign Out, My Account] Finance Home - Help Welcome [Sign In] To track stocks & more, Register Financial NewsEnter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup Press ReleaseSource: Market Strategies, Inc.

Market Strategies Announces 'HALO' Effect of ASCO 2005 Still Driving Oncologists' Prescribing Behavior for GenentechThursday September 8, 10:04 am ET Celgene's Revlimid Still 'Most Interesting' Agent for MDSSorafenib and Sutent Still 'Most Interesting' Agents for RCCBMS' Oral Kinase Inhibitor the 'Most Interesting' Agent for CML and GIST NEW PROVIDENCE, N.J., Sept.

8 /PRNewswire/ - On Thursday, September 8, 2005, Market Strategies, Inc.

(MSI), an international, full-service custom and syndicated research and strategic consulting firm, announced new findings from its most recent research of Oncologists' perceptions and attitudes at ASCO 2005.

The research, conducted by MSI's Global Life Sciences division, focused on whether Oncologists' initial perceptions immediately following ASCO were still valid 10 weeks later and also whether ASCO's "halo" effect was sustainable for those products that were seen as "belles of the ball." The findings indicate that an overwhelming majority of physicians already have incorporated HERCEPTIN into their adjuvant treatment of HER2+ brea...

Read more...